Comparison of the population covered by the 2024 version of the WHO's hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines
10.3760/cma.j.cn501113-20240421-00218
- VernacularTitle:世界卫生组织2024年版乙型肝炎防治指南与中国指南抗病毒治疗覆盖人群的比较
- Author:
Bingqiong WANG
1
;
Shan SHAN
;
Yuanyuan KONG
;
Xiaoning WU
;
Jialing ZHOU
;
Yameng SUN
;
Shuyan CHEN
;
Hao WANG
;
Xiaoqian XU
;
Shuai XIA
;
Jidong JIA
;
Hong YOU
Author Information
1. 首都医科大学附属北京友谊医院肝病中心 国家消化系统疾病临床医学研究中心，北京 100050
- Keywords:
Chronic hepatitis B;
Hepatitis B virus;
World health organization;
Guideline;
Antivirulence;
Therapeutic
- From:
Chinese Journal of Hepatology
2024;32(6):525-531
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to compare the antiviral treatment similarities and differences in the population covered by the 2024 version of the World Health Organization's (WHO) hepatitis B prevention and treatment guidelines and the current Chinese hepatitis B prevention and treatment guidelines, so as to explore their impact on the indications for antiviral therapy in Chinese patients with chronic hepatitis B (CHB).Methods:The information of patients with chronic hepatitis B virus infection who did not receive antiviral treatment was collected through the registration database of the China Clinical Research Platform for Hepatitis B Elimination. Descriptive statistics were conducted on the demographic, blood, biochemical, and virological levels of patients according to the treatment recommendations of the two versions of the guidelines. The Mann-Whitney U test and χ2 test were used to compare the differences and proportional distribution of the treatment populations covered by the two guidelines. The χ2 test was used to analyze the coverage rate of different antiviral treatment indications.Results:A total of 21,134 CHB patients without antiviral treatment were enrolled. 69.4% of patients met the 2024 versions of the WHO guidelines' recommendations. 85.0% of patients met the current Chinese hepatitis B prevention and treatment guidelines. The WHO guidelines for antiviral therapy indications were met in younger patients with higher levels of ALT, AST, and APRI scores, as well as greater proportion of patients with higher viral loads (P<0.001). The WHO guidelines recommended a cut-off value of APRI>0.5, which raised the proportion of patients on antiviral therapy from 6.6% to 30.9%. 45.7% of patients met the antiviral indications for HBV DNA >2000 IU/ml with abnormal transaminase (ALT>30 U/L for males and ALT>19 U/L for females). The reduced APRI diagnostic cut-off value and ALT treatment threshold had further increased the treatment coverage rate by 91.6% in patients with chronic HBV infection in line with the 2024 versions of WHO guidelines.Conclusion:The reduction of the APRI diagnostic cut-off value and the ALT treatment threshold, based on the current hepatitis B guidelines of China, will further improve the treatment coverage of CHB patients.
